journal
MENU ▼
Read by QxMD icon Read
search

Clinical Colorectal Cancer

journal
https://www.readbyqxmd.com/read/28223103/her2-amplification-and-cetuximab-efficacy-in-patients-with-metastatic-colorectal-cancer-harboring-wild-type-ras-and-braf
#1
Jae Ho Jeong, Jihun Kim, Yong Sang Hong, Dalyong Kim, Jeong Eun Kim, Sun Young Kim, Kyu-Pyo Kim, Young-Kwang Yoon, Deokhoon Kim, Sung-Min Chun, Yangsoon Park, Se Jin Jang, Tae Won Kim
BACKGROUND: Cetuximab has shown clinical benefit in patients with metastatic colorectal cancer (mCRC) harboring wild-type RAS. Human epidermal growth factor receptor 2 (HER2) amplification may be a mechanism of cetuximab resistance. We evaluated the association between HER2 amplification and cetuximab efficacy in patients with mCRC harboring wild-type RAS and BRAF. PATIENTS AND METHODS: Between December 2003 and June 2013, we identified 142 patients with mCRC whose tumors harbored both wild-type exons 2, 3, and 4 in KRAS and NRAS, and wild-type exon 15 in BRAF using high throughput sequencing (OncoMap version 4...
January 25, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28216247/oncologic-outcomes-of-oral-adjuvant-chemotherapy-regimens-in-stage-iii-colon-cancer-tegafur-uracil-plus-leucovorin-versus-capecitabine
#2
Jo Tashiro, Shigeki Yamaguchi, Toshimasa Ishii, Hiroka Kondo, Kiyoka Hara, Hiroki Shimizu, Kenichi Takemoto, Asami Suzuki
INTRODUCTION: Although several major trials of treatment for stage III colon cancer have been reported, no study has compared oral adjuvant chemotherapy regimens using tegafur-uracil in combination with leucovorin (UFT/LV) and capecitabine (CAPE) alone. This study compared the oncologic outcomes of treatment with these 2 oral regimens. PATIENTS AND METHODS: Records of patients with stage III colon cancer who underwent curative surgery and adjuvant chemotherapy from April 2007 and September 2014 were retrospectively reviewed...
January 25, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28216246/effect-of-kras-and-braf-mutations-on-survival-of-metastatic-colorectal-cancer-after-liver-resection-a-systematic-review-and-meta-analysis
#3
Federica Tosi, Elena Magni, Alessio Amatu, Gianluca Mauri, Katia Bencardino, Mauro Truini, Silvio Veronese, Luciano De Carlis, Giovanni Ferrari, Michele Nichelatti, Andrea Sartore-Bianchi, Salvatore Siena
BACKGROUND: The purpose of the study was to evaluate whether the mutational status of Kirsten rat sarcoma viral oncogene homolog (KRAS) or b-viral oncogene homolog B1 (BRAF) could be an independent prognostic factor in the subset of patients with colorectal cancer liver metastases (CRLM) who undergo complete liver resection. MATERIALS AND METHODS: A systematic literature review was performed to identify articles reporting relapse-free survival (RFS) and/or overall survival (OS) of patients who underwent complete liver resection for CRLM, stratified according to KRAS and BRAF mutational status...
January 25, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28209483/a-new-size-based-platform-for-circulating-tumor-cell-detection-in-colorectal-cancer-patients
#4
Bo Young Oh, Jhingook Kim, Woo Yong Lee, Hee Cheol Kim
BACKGROUND: Circulating tumor cells (CTCs) might play a significant role in cancer progression and metastasis. However, the ability to detect CTCs is limited, especially in cells undergoing epithelial-mesenchymal transition. In this study, we evaluated a new size-based CTC detection platform and its clinical efficacy in colorectal cancer. PATIENTS AND METHODS: Blood samples were obtained from 76 patients with colorectal cancer and 20 healthy control subjects for CTC analysis...
January 25, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28209482/effectiveness-of-a-tailored-anterior-saturation-band-in-the-improvement-of-the-image-quality-of%C3%A2-pelvic-magnetic-resonance-for-assessing-rectal%C3%A2-cancer
#5
Chen-Chang Lee, Po-Chou Chen, Hong-Hwa Chen, Chung-Cheng Huang, Li-Han Lin, Shu-Hang Ng, Min-Chi Chen, Sheung-Fat Ko
PURPOSE: We sought to test the effectiveness of the application of a tailored anterior saturation band (ASB) to improve the image quality of pelvic magnetic resonance imaging (MRI) for assessing rectal cancer. METHODS: A total of 165 patients with MRI assessment of rectal cancer between 2013 and 2015 were included. The image quality scores (4-point scale: 1, nondiagnostic through 4, excellent) of MRI without and with tailored ASBs were compared. Sensitivity, specificity, positive and negative predictive values, and accuracy of pelvic MRIs with and without a tailored ASB for T-staging in 65 patients with direct surgery and 67 patients with chemoradiotherapy before surgery were evaluated...
January 25, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28089507/gastrointestinal-perforation-and-fistula-formation-in-5-patients-with-colorectal-cancer-during-treatment-with-regorafenib
#6
Ayako Doi, Yasutoshi Kuboki, Kohei Shitara, Shota Fukuoka, Hideaki Bando, Wataru Okamoto, Takashi Kojima, Toshihiko Doi, Atsushi Ohtsu, Takayuki Yoshino
No abstract text is available yet for this article.
December 28, 2016: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28065664/racial-differences-in-stage-iv-colorectal-cancer-survival-in-younger-and-older-patients
#7
Kristin Wallace, Allan DeToma, David N Lewin, Shaoli Sun, Don Rockey, Carolyn D Britten, Jennifer D Wu, Aissatou Ba, Anthony J Alberg, Elizabeth G Hill
INTRODUCTION: African Americans (AAs) compared with European Americans (EAs) have poorer stage-specific survival from colorectal cancer (CRC). Recent reports have indicated that the racial difference in survival has worsened over time, especially among younger patients. To better characterize this association, we used population-based Surveillance, Epidemiology, and End Results registry data to evaluate the effect of race on stage IV CRC survival in patients aged < 50 and ≥ 50 years...
December 7, 2016: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28040407/from-shelf-to-bedside-wearable-electronic-activity-monitoring-technologies-might-assist-oncologists-in-functional-performance-status-assessment-of-older-cancer-patients
#8
Ciara M Kelly, Armin Shahrokni
No abstract text is available yet for this article.
November 30, 2016: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27553907/metastatic-colorectal-cancer-in-hispanics-treatment-outcomes-in-a-treated-population
#9
Maryam Shabihkhani, Steven S Yu, Dongyun Yang, Sonia Lin, Ann S Hamilton, Heinz-Josef Lenz, Afsaneh Barzi
BACKGROUND: In United States Hispanics have disparities in the presentation and outcome of colorectal cancer (CRC) largely attributed to their late presentation and lower socioeconomic status. Impact of treatment, especially in the metastatic setting, in the observed outcome is an unexplored area. We explored the role of treatment in the outcome of metastatic CRC we performed a retrospective analysis to assess the contribution of demographics, tumor characteristics, and health care setting on survival differences...
December 2016: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27553906/the-potential-value-of-immunotherapy-in-colorectal-cancers-review-of-the-evidence-for-programmed-death-1-inhibitor-therapy
#10
REVIEW
James W T Toh, Paul de Souza, Stephanie H Lim, Puneet Singh, Wei Chua, Weng Ng, Kevin J Spring
Colorectal cancers (CRCs) have been identified as potential targets for immunotherapy with programmed cell death (PD)-1 inhibitors. English-language publications from MedLine and Embase that evaluated PD-1/PD ligand 1 (PD-L1) in the CRC tumor microenvironment and clinical trials that assessed PD-1 inhibitors were included. Sixteen abstracts were screened. Fifteen met the inclusion criteria. After review of the full texts, this resulted in a final reference list of 8 studies eligible for review. Five studies that assessed PD-1/PD-L1 in CRC and 3 trials that assessed PD-1 inhibitors were included...
December 2016: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27521066/the-pharmacological-costs-of-first-line-therapies-in-unselected-patients-with-advanced-colorectal-cancer-a-review-of-published-phase-iii-trials
#11
REVIEW
Jacopo Giuliani, Andrea Bonetti
In light of the relevant expenses of pharmacologic interventions, it might be interesting to make a balance between the cost of the new drugs administered and the difference in progression-free survival in first-line treatments for advanced colorectal cancer. We calculated the pharmacologic costs necessary to get the benefit in progression-free survival for each trial. The costs are from the pharmacy of our hospital in Legnago, Italy. We evaluated 28 phase III randomized controlled trials that included 19,958 patients...
December 2016: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27507128/a-phase-ii-study-of-xelox-and-cetuximab-as-first-line-therapy-in-patients-with-kras-wild-type-metastatic-colorectal-cancer-fleet2-study
#12
Shoichi Hazama, Hiromichi Maeda, Shigeyoshi Iwamoto, Ho Min Kim, Hiroyoshi Takemoto, Kenji Kobayashi, Junichi Sakamoto, Naoki Nagata, Koji Oba, Hideyuki Mishima
BACKGROUND: Despite the comparable clinical benefit of XELOX (capecitabine with oxaliplatin) and FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin), the value of XELOX treatment in combination with cetuximab for metastatic colorectal cancer (mCRC) remains largely unknown. PATIENTS AND METHODS: In this clinical trial we evaluated the efficacy and safety of weekly/biweekly cetuximab administration combined with biweekly XELOX in patients with previously untreated v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) wild type mCRC...
December 2016: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27474080/pretreatment-serum-folate-levels-and-toxicity-efficacy-in-colorectal-cancer-patients-treated-with-5-fluorouracil-and-folinic-acid
#13
Michael Yan, Cheryl Ho, Eric Winquist, Derek Jonker, Daniel Rayson, Larry Stitt, Sonya Tokmakejian, Anna Tomiak, Mark D Vincent
BACKGROUND: 5-Fluorouracil (5-FU) chemotherapy is associated with severe and unpredictable toxicity in a significant proportion of patients. 5,10-Methylenetetrahydrofolate and 5-fluorodeoxyuridine monophosphate bind to thymidylate synthase and together inhibit its function, resulting in cytotoxicity. We hypothesized that susceptibility to 5-FU toxicity might be related to individual differences in the serum components of folate metabolism affecting intracellular 5,10-methylenetetrahydrofolate levels...
December 2016: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27435761/association-between-proton-pump-inhibitors-and-metronomic-capecitabine-as-salvage-treatment-for-patients-with-advanced-gastrointestinal-tumors-a-randomized-phase-ii-trial
#14
Paolo Marchetti, Annalisa Milano, Chiara D'Antonio, Adriana Romiti, Rosa Falcone, Michela Roberto, Stefano Fais
The acidification of extracellular compartment represents a conceivable mechanism of drug resistance in malignant cells. In addition, it has been reported to drive proliferation and promote invasion and metastasis. Experimental evidence has shown that proton pump inhibitors can counteract tumor acidification and restore sensitivity to anticancer drugs. Moreover, early clinical data have supported the role of proton pump inhibitors in anticancer treatments. Metronomic capecitabine has demonstrated beneficial effects as salvage chemotherapy for heavily pretreated or frail patients with gastrointestinal cancer...
December 2016: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27324983/tas-102-safety-in-metastatic-colorectal-cancer-results-from-the-first-postmarketing-surveillance-study
#15
Takayuki Yoshino, Hiroyuki Uetake, Naohiro Fujita, Takaaki Furuta, Jun Katori, Naoko Hara, Kei Muro
BACKGROUND: Unexpected toxicities of newly approved drugs might be revealed in clinical practice after market launch. This postmarketing surveillance study investigated expected and unexpected adverse drug reactions (ADRs) of TAS-102 in clinical practice in the first 6 months after market launch. PATIENTS AND METHODS: All metastatic colorectal cancer (mCRC) patients (pts) received TAS-102 35 mg/m(2) as a starting dose orally twice daily for 5 consecutive days, with 2 days of rest per week for 2 weeks, followed by a 14-day rest period...
December 2016: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27316919/interim-fluorine-18-fluorodeoxyglucose-positron-emission-tomography-computed-tomography-to-predict-pathologic-response-to-preoperative-chemoradiotherapy-and-prognosis-in-patients-with-locally-advanced-rectal-cancer
#16
Phillip J Koo, Seong-Jang Kim, Samuel Chang, Jennifer J Kwak
INTRODUCTION: The goal of the present study was to investigate the predictive and prognostic values of interim fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) parameters for the prediction of a complete pathologic response (pCR) in patients with locally advanced rectal cancer (LARC) who had received preoperative chemoradiotherapy (PCRT). PATIENTS AND METHODS: A total 103 patients with LARC were included in the present study...
December 2016: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27301717/colorectal-cancer-statistics-from-the-veterans-affairs-central-cancer-registry
#17
Leah L Zullig, Valerie A Smith, George L Jackson, Susanne Danus, Merritt Schnell, Jennifer Lindquist, Dawn Provenzale, Morris Weinberger, Michael J Kelley, Hayden B Bosworth
BACKGROUND: Colorectal cancer (CRC) is a common and potentially deadly disease. Although the United States has robust cancer data reporting, information from the Department of Veterans Affairs (VA) healthcare system has often been underrepresented in national cancer data sources. We describe veterans with incident CRC in terms of their patient and tumor characteristics and mortality. PATIENTS AND METHODS: Patients diagnosed or treated with CRC at any VA institution in the fiscal years 2009 to 2012 were identified using 3 data sources: (1) VA Central Cancer Registry (VACCR); (2) VA Corporate Data Warehouse; and (3) VA Reports and Measures Portal...
December 2016: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27297446/surgical-and-oncologic-outcomes-after-major-liver-surgery-and-extended-hemihepatectomy-for-colorectal-liver-metastases
#18
Inge Ubink, Jennifer M J Jongen, Maarten W Nijkamp, Eelco F J Meijer, Thomas T Vellinga, Richard van Hillegersberg, I Quintus Molenaar, Inne H M Borel Rinkes, Jeroen Hagendoorn
PURPOSE: To determine the surgical and oncologic outcomes after major liver surgery for colorectal liver metastases (CRLM) at a Dutch University Hospital. PATIENTS AND METHODS: Consecutive patients with CRLM who had undergone major liver resection, defined as ≥ 4 liver segments, between January 2000 and December 2015 were identified from a prospectively maintained database. RESULTS: Major liver surgery was performed in 117 patients. Of these, 26 patients had undergone formal extended left or right hemihepatectomy...
December 2016: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27262896/pancreas-adenocarcinoma-ascites-clinical-manifestations-and-management-implications
#19
Angel Mier Hicks, Joanne Chou, Marinela Capanu, Maeve A Lowery, Kenneth H Yu, Eileen M O'Reilly
BACKGROUND: Ascites develops in a subset of patients with pancreatic adenocarcinoma (PAC) at presentation or as the disease advances. Limited data exist on the prognostic importance of malignant ascites in PAC. Our hypothesis is that this information will provide an understanding of the natural history and facilitate management decisions. METHODS: We conducted a retrospective analysis of 180 patients treated at Memorial Sloan Kettering Cancer Center diagnosed between January 1, 2009 and December 31, 2014, with PAC and with ascites either at presentation or that developed during the disease course...
December 2016: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27262895/phase-2-trial-of-metformin-combined-with-5-fluorouracil-in-patients-with-refractory-metastatic-colorectal-cancer
#20
Vanessa C Miranda, Maria Ignez Braghiroli, Luiza Dib Faria, Giovanni Bariani, Alexandra Alex, João Evangelista Bezerra Neto, Fernanda C Capareli, Jorge Sabbaga, Juliana Ferreira Lobo Dos Santos, Paulo M Hoff, Rachel P Riechelmann
BACKGROUND: Observational and preclinical studies have suggested that metformin has antitumor effects in solid tumors, including colorectal cancer (CRC). However, the effects of metformin in CRC have not been tested in clinical trials. PATIENTS AND METHODS: This was a single-center, single-arm phase 2 clinical trial where histologically confirmed CRC patients with measurable and progressing metastatic disease previously treated with 5-fluorouracil (5-FU), irinotecan, oxaliplatin, and an anti-epidermal growth factor receptor (if the tumor was RAS wild type) were enrolled to receive metformin 850 mg orally continuously 2 times a day plus 5-FU 425 mg/m(2) and leucovorin 50 mg intravenously weekly until disease progression, unacceptable toxicity, or withdrawal of consent...
December 2016: Clinical Colorectal Cancer
journal
journal
39741
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"